Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lebrikizumab - Roche

Drug Profile

Lebrikizumab - Roche

Alternative Names: MILR1444A; MILR1444Ab; RG-3637; RO-5490255; TNX-650

Latest Information Update: 23 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tanox
  • Developer Chugai Pharmaceutical; Comprehensive Clinical Research Network; Dermira; Genentech; Roche; Tanox
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Hodgkin's disease; Idiopathic pulmonary fibrosis

Most Recent Events

  • 17 Oct 2019 Safety and efficacy data from a phase IIb trial in Atopic dermatitis released by Dermira
  • 09 Oct 2019 Phase-III clinical trials in Atopic dermatitis (In adults, In adolescents) in USA, Europe, Asia (SC)
  • 25 Jun 2019 Almirall exercises its option with Dermira to license rights to Lebrikizumab in Europe for Atopic Dermatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top